Suit filed in India to close Ranbaxy plants, probe company

06/10/2013 | BioSpectrum Asia

Following a $500 million settlement with the US FDA over selling adulterated drugs, the generic-drug firm Ranbaxy Laboratories is facing a public-interest lawsuit in India to shutter the two Indian manufacturing plants involved in the FDA settlement and launch a companywide investigation. The lawsuit alleges "outright fraud, in which the company knowingly sold substandard drugs around the world." Ranbaxy disputed the allegations, stating that all of its products are safe and effective.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ